
    
      Endostar have anti-tumor activity by against vascular endothelial growth factor for initial
      treatment. This study was designed to evaluate the safety and efficacy of Endostar Continued
      vein-pumping Combining with Gemcitabine-Cisplatin (GP)chemotherapy in patients with NSCLC,and
      seeking for more effective injection.
    
  